Which neurotransmitter hypothesis best explains the therapeutic mechanism of antipsychotic drugs in schizophrenia?

Explanation

## Dopamine Hypothesis of Schizophrenia **Key Point:** The dopamine hypothesis is the cornerstone neurochemical theory of schizophrenia. Hyperactivity in mesolimbic dopamine pathways drives positive symptoms, while hypoactivity in mesocortical pathways contributes to negative and cognitive symptoms. ### Dopamine Pathway Dysfunction in Schizophrenia ```mermaid flowchart TD A[Dopamine Dysregulation]:::outcome --> B{Pathway Affected?}:::decision B -->|Mesolimbic| C[↑ DA activity]:::outcome C --> D[Positive symptoms:<br/>Hallucinations, Delusions]:::outcome B -->|Mesocortical| E[↓ DA activity]:::outcome E --> F[Negative & Cognitive symptoms:<br/>Apathy, Poverty of speech, Cognitive impairment]:::outcome B -->|Nigrostriatal| G[Blocked by antipsychotics]:::action G --> H[Extrapyramidal side effects]:::urgent B -->|Tuberoinfundibular| I[Blocked by antipsychotics]:::action I --> J[Hyperprolactinemia]:::urgent ``` ### Mechanism of Antipsychotic Action **High-Yield:** All antipsychotics (typical and atypical) block D2 dopamine receptors, particularly in mesolimbic and mesocortical regions. This blockade: - **Reduces positive symptoms** (hallucinations, delusions) via mesolimbic pathway inhibition - **May worsen negative symptoms** via mesocortical pathway inhibition (especially typical antipsychotics) - **Causes extrapyramidal side effects** via nigrostriatal pathway blockade - **Causes hyperprolactinemia** via tuberoinfundibular pathway blockade **Clinical Pearl:** Atypical antipsychotics have a faster D2 dissociation rate and greater serotonin 5-HT2A antagonism, which may explain their superior efficacy for negative symptoms and lower extrapyramidal side effect burden compared to typical antipsychotics. **Mnemonic:** **DAMP** — Dopamine D2 blockade (mesolimbic/mesocortical), Atypical agents have faster dissociation, Mesocortical hypoactivity worsens negative symptoms, Positive symptoms respond to mesolimbic blockade. ### Why Other Neurotransmitter Systems Are Secondary | Neurotransmitter | Role in Schizophrenia | Antipsychotic Action | |---|---|---| | **Dopamine D2** | Primary pathology | Primary therapeutic target | | **Serotonin 5-HT2A** | Modulates dopamine; involved in cognition | Blocked by atypical antipsychotics (adjunctive benefit) | | **GABA** | Reduced inhibition in schizophrenia | Not primary antipsychotic target | | **Acetylcholine** | Cognitive dysfunction | Not primary antipsychotic target | [cite:Harrison's Principles of Internal Medicine 21e Ch 297]